VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the uptake, (semi-)quantification and localization
of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue,
surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical
specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using
fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW
is assessed. Another purpose is to assess the abilities of three different fluorescent signal
detection systems to detect the fluorescent signal pre- and intra-operatively.